OncoMatch

OncoMatch/Clinical Trials/NCT05583071

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Is NCT05583071 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tafasitamab and Lenalidomide for non-hodgkin lymphoma.

Phase 2RecruitingUniversity of CologneNCT05583071Data as of Jun 2026Location: Germany

Treatment: Tafasitamab · Lenalidomide · Rituximab · MethotrexatePilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Rituximab

Chemotherapy

Methotrexate

Endocrine / hormonal

Lenalidomide

Other

Tafasitamab

Cancer type

Non-Hodgkin Lymphoma

Demographics

Ages ≤ 99

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: any treatment for PCNSL

Exception: pre-phase treatment comprising steroid treatment and/or single application of rituximab 375 mg/m² and methotrexate 3.5 g/m²

Prior treatment for PCNSL with the exception of a pre-phase treatment comprising steroid treatment and / or single application of rituximab 375 mg/m² and methotrexate 3.5 g/m²

Lab requirements

Blood counts

white blood cell (wbc) count ≥ 3000/µl or absolute neutrophil count (anc) ≥ 1000/µl; platelets ≥ 50.000/µl; hemoglobin > 8.0 g/dl

Kidney function

serum creatinine estimated glomerular filtration rate (mdrd) ≥ 50 ml/min

Liver function

alat and asat ≤ 3 uln; bilirubin ≤ 2.0 mg/dl (except for meulengracht disease)

Cardiac function

cardiac ejection fraction ≥ 40%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05583071 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 99 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify